Quince Therapeutics, Inc.

SecurityQNCX / Quince Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership248,011 shares
Latest Disclosed Value $ 25,148
State Street Corp reports 7.55% increase in ownership of QNCX / Quince Therapeutics, Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 248,011 shares of Quince Therapeutics, Inc. (US:QNCX) valued at $25,148 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 230,611 shares of Quince Therapeutics, Inc.. This represents a change in shares of 7.55% during the quarter. The current value of the position is $272,812 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F QUINCE THERAPEUTICS COM 22053A107 248,011 17,400 7.55 25 -96.76 0.0000
2026-02-13 2025-12-31 13F QUINCE THERAPEUTICS COM 22053A107 230,611 32,500 16.40 773 139.75 0.0000
2025-11-14 2025-09-30 13F QUINCE THERAPEUTICS COM 22053A107 198,111 73,200 58.60 323 56.31 0.0000
2025-08-14 2025-06-30 13F QUINCE THERAPEUTICS COM 22053A107 124,911 0 0.00 206 24.10 0.0000
2025-05-15 2025-03-31 13F QUINCE THERAPEUTICS COM 22053A107 124,911 0 0.00 166 -28.76 0.0000
2025-02-14 2024-12-31 13F QUINCE THERAPEUTICS COM 22053A107 124,911 68,300 120.65 234 441.86 0.0000
2024-11-14 2024-09-30 13F QUINCE THERAPEUTICS COM 22053A107 56,611 0 0.00 44 2.38 0.0000
2024-08-14 2024-06-30 13F QUINCE THERAPEUTICS COM 22053A107 56,611 0 0.00 42 -30.00 0.0000
2024-05-15 2024-03-31 13F QUINCE THERAPEUTICS COM 22053A107 56,611 0 0.00 60 1.69 0.0000
2024-02-14 2023-12-31 13F QUINCE THERAPEUTICS COM 22053A107 56,611 0 0.00 59 -6.35 0.0000
2023-11-14 2023-09-30 13F QUINCE THERAPEUTICS COM 22053A107 56,611 0 0.00 63 -25.88 0.0000
2023-08-14 2023-06-30 13F QUINCE THERAPEUTICS COM 22053A107 56,611 -800 -1.39 85 -4.49 0.0000
2023-05-15 2023-03-31 13F QUINCE THERAPEUTICS COM 22053A107 57,411 0 0.00 90 147.22 0.0000
2023-05-15 2022-12-31 13F/A-99 QUINCE THERAPEUTICS COM 22053A107 57,411 0 0.00 37 -52.63 0.0000
2023-05-15 2022-12-31 13F QUINCE THERAPEUTICS COM 22053A107 57,411 0 37 0.0000
2022-11-15 2022-09-30 13F QUINCE THERAPEUTICS COM 22053A107 57,411 0 0.00 76 -40.16 0.0000
2022-08-15 2022-06-30 13F CORTEXYME COM 22053A107 57,411 -361,134 -86.28 127 -95.10 0.0000
2022-05-16 2022-03-31 13F CORTEXYME COM 22053A107 418,545 20,703 5.20 2,591 -48.40 0.0001
2022-02-14 2021-12-31 13F CORTEXYME COM 22053A107 397,842 -443,178 -52.70 5,021 -93.49 0.0002
2021-11-15 2021-09-30 13F CORTEXYME COM 22053A107 841,020 -121,795 -12.65 77,088 51.07 0.0041
2021-08-16 2021-06-30 13F CORTEXYME COM 22053A107 962,815 -103,065 -9.67 51,029 32.87 0.0027
2021-07-09 2021-03-31 13F/A-1 CORTEXYME COM 22053A107 1,065,880 241,230 29.25 38,404 67.64 0.0022
2021-05-17 2021-03-31 13F CORTEXYME COM 22053A107 1,065,880 241,230 38,404 0.0022
2021-02-16 2020-12-31 13F CORTEXYME COM 22053A107 824,650 538,320 188.01 22,909 60.01 0.0014
2020-11-10 2020-09-30 13F CORTEXYME COM 22053A107 286,330 1,150 0.40 14,317 8.43 0.0010
2020-08-14 2020-06-30 13F CORTEXYME COM 22053A107 285,180 91,128 46.96 13,204 49.18 0.0010
2020-06-19 2020-03-31 13F/A-1 CORTEXYME COM 22053A107 194,052 18,125 10.30 8,851 -10.39 0.0008
2020-05-11 2020-03-31 13F CORTEXYME COM 22053A107 194,052 18,125 8,851 777.2960
2020-02-06 2019-12-31 13F CORTEXYME COM 22053A107 175,927 125,098 246.12 9,877 679.56 0.0007
2019-11-14 2019-09-30 13F CORTEXYME COM 22053A107 50,829 12,384 32.21 1,267 29.82 0.0001
2019-08-14 2019-06-30 13F CORTEXYME COM 22053A107 38,445 38,445 976 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.